ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Statistical Considerations in the Evaluation of Continuous Biomarkers.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preoperative inflammation-based biomarkers and postoperative pulmonary complications after lung resection for lung cancer: a systematic review with selective exploratory quantitative synthesis.Frontiers in surgery · 2026Pooled it
- L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.Nature communications · 2024Trial
- Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis.Neurology · 2026Article
- Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial.Nature medicine · 2026Article
- Plasma Malondialdehyde Reference Interval and Its Associations with Lifestyle Risk Factors in Thai Undergraduate Students: A Single-Center Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Beyond single cut-off values in ultrasound: limitations and implications for context-aware radiology reporting.Insights into imaging · 2026Review
- Review
- Circulating Cytokines in Melanoma Prognosis: Current Evidence and Future Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Observational
- Innovations in biomarker stratification for precision oncology.Clinical and experimental medicine · 2026Review
- Predicting Postoperative Survival in Patients With Malignant Biliary Obstruction Using an Interpretable Machine Learning Model: A Multicenter Study.Cancer medicine · 2026Article
- Predictive Biomarkers for Asymptomatic Adults: Opportunities, Risks, and Guidance for General Practice.Diagnostics (Basel, Switzerland) · 2026Review
- PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression.Oncology research · 2026Article
- Biomarker-driven optimal designs for patient enrollment restriction.Statistical methods in medical research · 2025Article
- Evaluation of Optimal Cut-Offs and Dichotomous Combinations for Two Biomarkers to Improve Patient Selection.Therapeutic innovation & regulatory science · 2025Article
- Methodological Insights on Biomarker-Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency.Clinical pharmacology and therapeutics · 2025Review
- Discretizing multiple continuous predictors with U-shaped relationships with lnOR: introducing the recursive gradient scanning method in clinical and epidemiological research.BMC medical research methodology · 2025Article
- Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy.Current rheumatology reports · 2024Review
- Article
- Circulating biomarkers of kidney angiomyolipoma and cysts in tuberous sclerosis complex patients.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Discovery of biomarkers has been steadily increasing over the past decade. Although a plethora of biomarkers has been reported in the biomedical literature, few have been sufficiently validated for broader clinical applications. One particular challenge that may have hindered the adoption of biomarkers into practice is the lack of reproducible biomarker cut points. In this article, we attempt to identify some common statistical issues related to biomarker cut point identification and provide guidance on proper evaluation, interpretation, and validation of such cut points. First, we illustrate how discretization of a continuous biomarker using sample percentiles results in significant information loss and should be avoided. Second, we review the popular "minimal-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.